MedPath

WP02 Continued Access Study

Not Applicable
Terminated
Conditions
Liver Transplantation
Interventions
Device: Normothermic Machine Perfusion (NMP)
Registration Number
NCT04862156
Lead Sponsor
OrganOx Ltd.
Brief Summary

The single-arm continued access phase will be used to collect additional effectiveness and safety data to support the objectives and outcomes of the original IDE pivotal study.

Detailed Description

Not available

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
19
Inclusion Criteria
  • Subject is 18 years of age or greater
  • Subject is registered as an active recipient on the UNOS waiting list for liver transplantation
  • Subject, or legally authorized representative, is able and willing to give informed consent and HIPAA authorization
  • Subject is able and willing to comply with all study requirements
Exclusion Criteria
  • Subject requiring all of the following at the time of transplantation:

    1. Oxygen therapy via a ventilator/respirator
    2. Inotropic support
    3. Renal replacement therapy
  • Subject has acute/fulminant liver failure (UNOS status 1A)

  • Subject undergoing simultaneous transplantation of more than one organ (e.g., liver and kidney)

  • Subject is pregnant (as confirmed by urine or serum pregnancy test) or nursing

  • Concurrent enrollment in another clinical trial. Subjects enrolled in clinical trials or registries where only measurements and/or samples are taken (NO TEST DEVICE or TEST DRUG USED) are allowed to participate.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Normothermic Machine Perfusion (NMP)Normothermic Machine Perfusion (NMP)Following the routine retrieval procedure of the liver, it will be placed on the OrganOx metra for Normothermic Machine Perfusion (NMP) for transport per the Investigational Plan and the Instructions for Use.
Primary Outcome Measures
NameTimeMethod
Incidence of Early Allograft Dysfunction (EAD)7 days

Severity of immediate graft injury as measured by early allograft dysfunction (EAD).

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (7)

Washington University

🇺🇸

Saint Louis, Missouri, United States

University of Wisconsin-Madison

🇺🇸

Madison, Wisconsin, United States

University of Colorado

🇺🇸

Aurora, Colorado, United States

Loyola University Chicago

🇺🇸

Maywood, Illinois, United States

University of Michigan

🇺🇸

Ann Arbor, Michigan, United States

Duke University

🇺🇸

Durham, North Carolina, United States

University of Pennsylvania

🇺🇸

Philadelphia, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath